Could a One-Two punch of CAR-T and stem cell transplant beat myeloma early?
NCT ID NCT07169500
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new treatment for young adults (18-55) newly diagnosed with multiple myeloma. It uses a patient's own immune cells, engineered to attack the cancer (BCMA-CART), either alone or combined with a stem cell transplant. The goal is to see if this approach can wipe out the cancer more deeply and keep it away longer. The trial is currently recruiting 50 participants to evaluate safety and early effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BCMA-targeted CAR-T cells (a type of immune cell therapy) with or without stem cell transplant
What this could lead to
If successful, this could offer a more effective way to control multiple myeloma early on, potentially leading to longer remission periods for young patients.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply broadly. CAR-T therapy can cause serious side effects like cytokine release syndrome, and the long-term benefits are still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••